← ALNYLAM PHARMACEUTICALS, INC.
| Annual Trend | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $47.2m |
$89.9m
+90.66%
|
$74.9m
-16.69%
|
$219.8m
+193.36%
|
$492.9m
+124.28%
|
$844.3m
+71.31%
|
$1.0b
+22.88%
|
$1.8b
+76.23%
|
$2.2b
+22.97%
|
$3.7b
+65.19%
|
$4.8b
+29.36%
|
|
| Cost of Revenue | $382.4m |
$0
-100.00%
|
$1.8m |
$25.1m
+1290.79%
|
$78.1m
+211.44%
|
$115.0m
+47.34%
|
$140.2m
+21.89%
|
$268.2m
+91.35%
|
$306.5m
+14.28%
|
$677.2m
+120.93%
|
$977.5m
+44.34%
|
|
| Gross Profit (Calculated) (derived) | ($335.2m) |
$89.9m
+126.82%
|
$73.1m
-18.69%
|
$194.7m
+166.31%
|
$414.8m
+113.06%
|
$729.3m
+75.81%
|
$897.2m
+23.03%
|
$1.6b
+73.87%
|
$1.9b
+24.46%
|
$3.0b
+56.40%
|
— | |
| Research and Development Expense | $382.4m | $390.6m | $505.4m | $655.1m | $654.8m | $792.2m | $883.0m | $1.0b | $1.1b | $1.3b | $1.5b | |
| General and Administrative Expense | $89.4m | $199.4m | $382.4m | $479.0m | $588.4m | $620.6m | $770.7m | $795.6m | $975.5m | $1.2b | $1.3b | |
| Operating Lease, Expense | — | — | — | — | $50.7m | $59.5m | $58.6m | $61.6m | — | — | — | |
| Operating Expenses | $471.7m | $590.0m | — | — | — | — | — | — | — | — | $3.8b | |
| Operating Income (Loss) | ($424.6m) |
($500.1m)
-17.78%
|
($814.7m)
-62.91%
|
($939.4m)
-15.31%
|
($828.4m)
+11.81%
|
($708.7m)
+14.46%
|
($785.1m)
-10.78%
|
($282.2m)
+64.06%
|
($176.9m)
+37.31%
|
$501.6m
+383.56%
|
$999.8m
+99.33%
|
|
| Investment Income, Net | $8.3m | $12.2m | $29.3m | $33.4m | — | — | — | — | — | — | — | |
| Gain (Loss) Related to Litigation Settlement | — | — | $20.6m | $0 | — | — | — | — | — | — | — | |
| Other Nonoperating Income (Expense) | $6.2m | ($3.0m) | $4.2m | $11.3m | $45.5m | ($2.0m) | ($109.4m) | ($125.7m) | ($180.6m) | $5.2m | — | |
| Interest Expense (non-operating) | — | — | $0 | $0 | $84.5m | $143.0m | $156.0m | $121.2m | $141.9m | $252.6m | $284.2m | |
| Income (Loss) from Continuing Operations before Income Taxes, Domestic | ($350.7m) | ($378.3m) | ($573.2m) | ($597.6m) | ($682.9m) | ($794.7m) | ($1.1b) | ($450.3m) | ($571.9m) | $18.3m | $766.3m | |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest | ($410.1m) | $500.1m | ($760.7m) | ($885.3m) | ($855.6m) | ($852.1m) | ($1.1b) | ($433.5m) | ($377.4m) | $323.2m | $766.3m | |
| Current Income Tax Expense (Benefit) | — | — | $1.6m | $2.8m | $5.9m | $3.4m | $5.6m | $7.4m | $7.5m | $11.6m | ($8.4m) | |
| Income Tax Expense (Benefit) | — | — | $823k | $863k | $2.7m | $680k | $4.2m | $6.7m | ($99.2m) | $9.4m | ($8.4m) | |
| Net Income (Loss) Attributable to Parent | ($410.1m) |
($490.9m)
-19.69%
|
($761.5m)
-55.13%
|
($886.1m)
-16.37%
|
($858.3m)
+3.14%
|
($852.8m)
+0.64%
|
($1.1b)
-32.64%
|
($440.2m)
+61.08%
|
($278.2m)
+36.82%
|
$313.7m
+212.79%
|
$774.7m
+146.92%
|
|
| Earnings Per Share, Basic | — | — | — | ($8.11) | ($7.46) | ($7.20) | ($9.30) | ($3.52) | ($2.18) | $2.39 | $5.87 | |
| Earnings Per Share, Diluted | ($4.79) | ($5.42) | ($7.57) | ($8.11) | ($7.46) | ($7.20) | ($9.30) | ($3.52) | ($2.18) | $2.33 | $5.74 | |
| Weighted Average Number of Shares Outstanding, Basic | — | — | — | 109.3m | 115.0m | 118.5m | 121.7m | 124.9m | 127.7m | 131.0m | 132.5m | |
| Weighted Average Number of Shares Outstanding, Diluted | — | — | — | 109.3m | 115.0m | 118.5m | 121.7m | 124.9m | 127.7m | 134.7m | 138.7m | |
| Additional Financial Items | ||||||||||||
| Costs and Expenses | — | — | $889.6m | $1.2b | $1.3b | $1.6b | $1.8b | $2.1b | $2.4b | $3.2b | — |
Values abbreviated: b = billions, m = millions, k = thousands. Per share data in USD.